Thyroid CancersNCT06958601
Safety and Efficacy of Transoral Robotic Thyroidectomy Versus Traditional Open Thyroidectomy for Thyroid Cancer
An observational study of Thyroid Cancers, run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University at 1 site in China.
Trial summary
In general, the utilization of the transoral vestibular approach in robotic surgery demonstrates efficacy comparable to that of traditional open surgery in the treatment of thyroid cancer. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Thyroid Cancers
- What is being tested?
- surgical procedure
- How many people
- 430 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2025to 31 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Thyroid cancer patients
Who may be able to join
- Age 18- 65 years old, both male and female
- Postoperative pathology was papillary thyroid carcinoma
- Clinical data integrity
Who cannot join
- Postoperative pathology was benign
- Clinical data are incomplete
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Analysis of the Safety and Efficacy of Transoral Robotic Thyroidectomy Versus Conventional Open Thyroidectomy
In general, the utilization of the transoral vestibular approach in robotic surgery demonstrates efficacy comparable to that of traditional open surgery in the treatment of thyroid cancer. This method not only reduces the length of hospitalization for patients but also ensures superior cosmetic outcomes in the cervical region, thus achieving truly scarless aesthetics. The feasibility of Transoral Vestibular Robotic Thyroidectomy (TOVRT) for tumors greater than 2 cm in diameter warrants further exploration in future studies; however, for tumors less than 2 cm in diameter, TOVRT emerges as a safe, reliable, and practical alternative, poised to establish itself as an innovative surgical modality.
- Conditions
- Thyroid Cancers
- Being tested
- surgical procedure
- Medical subject headings
- Thyroid Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
surgical procedureOther
Effectiveness of different surgical modalities in the treatment of thyroid cancer
| Study group | Role | What they receive |
|---|---|---|
| traditional open group | 1) General demographic information: including age, gender, ethnicity, etc. 2) Disease-related information: lesion size, lesion location, pathological type, parathyroid function (preoperative, first day postoperative, and one week postoperative), thyroid function (preoperative and one month postoperative), etc.3) Surgery-related information: occurrence of postoperative complications, total number of days of hospitalization following the operation, postoperative quality of life (dysphagia index, neck injury index), etc. Receives: Other: surgical procedure | |
| robotic group | 1) General demographic information: including age, gender, ethnicity, etc. 2) Disease-related information: lesion size, lesion location, pathological type, parathyroid function (preoperative, first day postoperative, and one week postoperative), thyroid function (preoperative and one month postoperative), etc.3) Surgery-related information: occurrence of postoperative complications, total number of days of hospitalization following the operation, postoperative quality of life (dysphagia index, neck injury index), etc. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Key Observational Indicators
Incidental parathyroidectomy rate
Measured: 6moths
Secondary outcomes (1)
Secondary observations
Incidence of hypoparathyroidism
Measured: 6months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2025
- Study start1 May 2025
- Primary completion31 May 2025
- Study completion31 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid CancersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 430 participants (actual)
Sponsor and investigators
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06958601
- Sponsor's protocol ID
- No.357[2024]
- Status last verified
- Jul 2026
- First submitted
- 6 Apr 2025
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Analysis of the Safety and Efficacy of Transoral Robotic Thyroidectomy Versus Conventional Open Thyroidectomy
- ClinicalTrials.gov ID
- NCT06958601
- Acronym / sponsor ID
- No.357[2024]
- Conditions
- Thyroid Cancers
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 430 participants (actual)
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 31 May 2025 (actual)
- Study completion
- 31 May 2025 (actual)
- First posted
- 6 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In general, the utilization of the transoral vestibular approach in robotic surgery demonstrates efficacy comparable to that of traditional open surgery in the treatment of thyroid cancer. This method not only reduces the length of hospitalization for patients but also ensures superior cosmetic outcomes in the cervical region, thus achieving truly scarless aesthetics. The feasibility of Transoral Vestibular Robotic Thyroidectomy (TOVRT) for tumors greater than 2 cm in diameter warrants further exploration in future studies; however, for tumors less than 2 cm in diameter, TOVRT emerges as a safe, reliable, and practical alternative, poised to establish itself as an innovative surgical modality.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| traditional open group | – | Other: surgical procedure1) General demographic information: including age, gender, ethnicity, etc. 2) Disease-related information: lesion size, lesion location, pathological type, parathyroid function (preoperative, first day postoperative, and one week postoperative), thyroid function (preoperative and one month postoperative), etc.3) Surgery-related information: occurrence of postoperative complications, total number of days of hospitalization following the operation, postoperative quality of life (dysphagia index, neck injury index), etc. |
| robotic group | – | –1) General demographic information: including age, gender, ethnicity, etc. 2) Disease-related information: lesion size, lesion location, pathological type, parathyroid function (preoperative, first day postoperative, and one week postoperative), thyroid function (preoperative and one month postoperative), etc.3) Surgery-related information: occurrence of postoperative complications, total number of days of hospitalization following the operation, postoperative quality of life (dysphagia index, neck injury index), etc. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Thyroid cancer patients
Key inclusion criteria (3 listed)
- Age 18- 65 years old, both male and female
- Postoperative pathology was papillary thyroid carcinoma
- Clinical data integrity
Key exclusion criteria (2 listed)
- Postoperative pathology was benign
- Clinical data are incomplete
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| surgical procedureEffectiveness of different surgical modalities in the treatment of thyroid cancer | Other | traditional open group |
Primary outcome
Key Observational Indicators
Time frame: 6moths
Incidental parathyroidectomy rate
1 secondary outcome
Secondary observations
Time frame: 6months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Thyroid Cancers
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Recruiting
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Thyroid Gland Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancers, run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Key Observational Indicators (time frame: 6moths). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.